Business Context and Reporting Period
Relmada Therapeutics, Inc. filed this Form 8-K on November 2, 2018, to report the additional closing of a private placement of securities. The Company, incorporated in Nevada, is a biopharmaceutical entity headquartered in New York. This filing details the third and final closing of an offering that began on October 12, 2018.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $1,349,509 received from the November 2 closing.
- Securities Issued: 1,499,456 shares of common stock sold at $0.90 per share.
- Warrants Issued: Five-year warrants to purchase 974,645 shares at an exercise price of $1.50 per share.
- Placement Agent Fees: Alexander Capital, LP received a cash fee of $154,267 (including a $12,206 expense allowance) and warrants to purchase 203,435 shares at $0.99 per share.
- Liquidity and Debt: The filing does not provide current cash balances, total debt, or liquidity ratios. The transaction represents a capital raise intended to improve liquidity.
Material Changes and Agreements
The primary material change is the increase in outstanding equity and warrant obligations following the November 2 closing. The Company entered into a Registration Rights Agreement requiring the registration of the newly issued shares and warrant shares. If the Company fails to file or declare the registration statement effective within the agreed timeframe, it is obligated to pay investors a penalty of 1% of the total purchase price per month, capped at 6% in the aggregate.
Outlook, Risks, and Contingencies
- Registration Risk: The Company faces a financial penalty contingency if it fails to timely register the securities sold in this offering.
- Regulatory Status: The securities were sold under Rule 506 of Regulation D to accredited investors and have not been registered for primary sale under the Securities Act of 1933.
- Management Commentary: The filing contains no forward-looking guidance, earnings outlook, or strategic commentary beyond the mechanics of the capital raise.
Investor Verification Checklist
- Verify the total aggregate proceeds raised across all three closings (October 12, October 18, and November 2) to assess total capital raised in this round.
- Confirm the status of the Registration Rights Agreement and whether the registration statement has been filed or declared effective to avoid penalty payments.
- Review the Company's most recent Form 10-Q or 10-K for updated cash balances and burn rate to understand the impact of the $1.35 million proceeds on runway.
- Check the total number of outstanding warrants and their dilution impact on existing shareholders.